```html

Rheumatic Mitral Stenosis – A Comprehensive Medical Guide

Overview

Rheumatic mitral stenosis (MS) is a narrowing of the mitral valve opening that results from chronic damage caused by rheumatic fever, an autoimmune reaction to infection with Group A Streptococcus. The malfunctioning valve obstructs blood flow from the left atrium to the left ventricle, eventually leading to increased pressure in the lungs and reduced cardiac output.

Who it affects: The condition predominantly occurs in low‑ and middle‑income countries where rheumatic fever is still common. In high‑income nations, it is now rare and usually seen in older adults who had rheumatic fever in childhood. Women are slightly more affected than men, reflecting the higher incidence of acute rheumatic fever in females during childhood.

Prevalence: According to the World Health Organization (WHO), rheumatic heart disease (RHD) affects an estimated 39 million people globally, and mitral stenosis accounts for roughly 30‑40 % of RHD cases [1]. In endemic regions (e.g., South Asia, sub‑Saharan Africa, the Pacific Islands) prevalence can be as high as 5–10 per 1,000 individuals, while in the United States and Western Europe it is <1 per 10,000 [2].

Symptoms

Symptoms develop slowly, often over many years, and may be absent in early disease. When they appear, they usually reflect left‑sided heart failure and reduced forward flow.

• Dyspnea on exertion – shortness of breath during activities that previously caused no problem.
• Orthopnea – difficulty breathing when lying flat; patients may need to sleep with extra pillows.
• Paroxysmal nocturnal dyspnea (PND) – sudden awakening with a feeling of suffocation.
• Fatigue and reduced exercise tolerance – due to decreased cardiac output.
• Palpitations – often caused by atrial fibrillation, a common arrhythmia in MS.
• Chest discomfort – typically not angina, but a sense of tightness from pulmonary congestion.
• Cough or wheeze – chronic pulmonary congestion can mimic asthma.
• Hemoptysis – coughing up blood, usually small amounts, from ruptured pulmonary vessels.
• Swelling of the ankles or abdomen (edema) – in advanced disease when right‑sided failure develops.
• Syncope or near‑syncope – especially during exertion, reflecting sudden drops in cardiac output.

Because the symptom profile overlaps with many other conditions, a thorough cardiac evaluation is essential.

Causes and Risk Factors

Primary cause

Rheumatic mitral stenosis is a sequela of rheumatic fever, an inflammatory disease that follows an untreated or inadequately treated Group A streptococcal pharyngitis. The immune response mistakenly attacks cardiac tissue, causing:

• Valve leaflet thickening
• Fusion of commissures (the points where leaflets meet)
• Calcification over decades

Risk factors

• Age – most patients present in the 3rd to 5th decade after years of gradual scarring.
• Geography & socioeconomic status – crowded living conditions, limited access to antibiotics, and poor health‑care infrastructure increase incidence.
• Gender – females have a slightly higher risk of developing rheumatic fever.
• Genetic susceptibility – certain HLA subtypes (e.g., HLA‑DR7) are linked with more severe rheumatic disease [3].
• Recurrent streptococcal infections – repeated episodes raise the likelihood of chronic valve damage.
• Delayed or insufficient antibiotic treatment – failure to eradicate the streptococcal infection allows the autoimmune cascade to continue.

Diagnosis

Diagnosing rheumatic mitral stenosis combines a detailed history, physical examination, and targeted investigations.

Clinical clues

• History of rheumatic fever or childhood sore throat.
• Mid‑diastolic “rumbling” murmur best heard at the apex with the patient in left lateral decubitus position.
• Opening snap – a high‑pitched sound immediately after the second heart sound, indicating a stiff mitral valve.
• Signs of left atrial enlargement (e.g., displaced apical impulse).

Imaging and tests

1. Echocardiography (transthoracic or transesophageal) – the gold standard. It measures:
   • Mitral valve area (MVA); severe stenosis is < 1.0 cm², moderate 1.0–1.5 cm².
   • Mean pressure gradient across the valve.
   • Presence of commissural fusion, leaflet thickening, and calcification.
   • Left atrial size and pulmonary artery pressures.
2. Electrocardiogram (ECG) – may show atrial fibrillation, left atrial enlargement, or right‑axis deviation.
3. Chest X‑ray – can reveal left atrial enlargement, pulmonary congestion, or calcification of the mitral annulus.
4. Cardiac catheterization – rarely needed now, but can quantify hemodynamics if non‑invasive data are inconclusive.
5. Blood tests – CBC, inflammatory markers (ESR, CRP) may be elevated if there is an active rheumatic process; thyroid function and BNP can help assess heart failure severity.

Treatment Options

Management aims to relieve symptoms, prevent complications, and correct the mechanical obstruction.

Medical therapy

• Diuretics (e.g., furosemide) – reduce pulmonary congestion and relieve dyspnea.
• Beta‑blockers or non‑dihydropyridine calcium channel blockers – control heart rate in atrial fibrillation, allowing longer diastolic filling.
• Anticoagulation – essential for patients with atrial fibrillation or a prior embolic event. Warfarin (target INR 2.0–3.0) is most widely used; direct oral anticoagulants (DOACs) may be considered in selected patients without mechanical valves.
• Anti‑inflammatory prophylaxis – long‑term intramuscular benzathine penicillin G every 3–4 weeks prevents recurrent streptococcal infections and halts further rheumatic damage (WHO recommendation) [1].
• Digoxin – used selectively for rate control in atrial fibrillation when beta‑blockers are contraindicated.

Interventional procedures

1. Percutaneous Balloon Mitral Valvotomy (PBMV) – a catheter‑based technique that splits fused commissures. Indicated for:
   • Wilkin’s score ≤8 (favorable valve morphology)
   • Severe stenosis (MVA < 1.5 cm²)
   • Absence of left atrial thrombus
   Success rates > 90 % with low peri‑procedural mortality [4].
2. Surgical commissurotomy – open‑heart surgery to separate fused leaflets; reserved for patients unsuitable for PBMV (e.g., heavily calcified valves).
3. Mitral valve replacement (MVR) – mechanical or bioprosthetic valve implantation. Indicated when:
   • Valve is heavily calcified or severely damaged.
   • Repeated PBMV attempts have failed.
   Mechanical valves require lifelong anticoagulation; bioprosthetic valves have limited durability but may avoid long‑term anticoagulation in selected patients.

Lifestyle and supportive measures

• Low‑sodium diet to minimise fluid retention.
• Regular, moderate‑intensity aerobic activity (e.g., walking) as tolerated; avoid high‑intensity exertion that can precipitate syncope.
• Vaccinations – influenza and pneumococcal vaccines reduce the risk of respiratory infections that could exacerbate heart failure.
• Weight management – obesity worsens dyspnea and increases atrial fibrillation risk.

Living with Rheumatic Mitral Stenosis

Daily management tips

• Medication adherence – set daily reminders; keep a medication list for any healthcare visit.
• Monitor symptoms – use a simple diary to record shortness of breath, weight changes, and irregular heartbeats. A sudden increase in weight (> 2 kg in 3 days) may signal fluid overload.
• Regular follow‑up – echocardiograms every 6–12 months, or sooner if symptoms change.
• Listen to your body – if you feel unusually fatigued, develop new palpitations, or notice swelling, contact your cardiologist promptly.
• Stay hydrated, but avoid excess fluids – a typical recommendation is 1.5–2 L/day unless your doctor advises otherwise.
• Travel considerations – bring a copy of your medication list, anticoagulation monitoring kit (if on warfarin), and ensure you have enough medication for the entire trip.

Psychosocial aspects

Chronic heart disease can cause anxiety and depression. Access to counseling, support groups for rheumatic heart disease, and stress‑reduction techniques (e.g., mindfulness, gentle yoga) can improve quality of life.

Prevention

Because rheumatic mitral stenosis is a downstream consequence of rheumatic fever, primary prevention focuses on preventing the initial streptococcal infection and treating it promptly.

1. Early diagnosis and treatment of strep throat – a single dose of oral penicillin V or a 10‑day course eradicates the bacteria in > 90 % of cases [5].
2. Community‑level interventions – school‑based screening programs, improved access to primary care, and public education about sore‑throat symptoms.
3. Secondary prophylaxis – for anyone who has had rheumatic fever, continuous penicillin injections every 3–4 weeks reduce recurrences by > 80 % [1].
4. Improving living conditions – reducing overcrowding, enhancing nutrition, and ensuring clean water help lower infection rates.

Complications

If left untreated, rheumatic mitral stenosis can lead to serious, potentially life‑threatening problems.

• Atrial fibrillation – loss of atrial contraction reduces cardiac output and raises stroke risk.
• Systemic embolism – thrombus formation in the enlarged left atrium can travel to the brain (stroke) or other organs.
• Pulmonary hypertension – chronic backward pressure damages pulmonary vessels, causing right‑ventricular strain.
• Right‑sided heart failure – eventual consequence of severe pulmonary hypertension.
• Hemoptysis – rupture of bronchial veins under high pressure.
• Infective endocarditis – damaged valve surfaces are vulnerable to bacterial colonisation.
• Pregnancy‑related complications – increased blood volume can precipitate decompensation; careful obstetric‑cardiac management is required.

When to Seek Emergency Care

---

References:
[1] World Health Organization. “Rheumatic Fever and Rheumatic Heart Disease.” WHO Fact Sheet, 2023.
[2] Mayo Clinic. “Rheumatic Heart Disease.” Updated 2024.
[3] Carapetis JR et al. “Epidemiology of rheumatic fever and rheumatic heart disease.” Nat Rev Cardiol. 2022;19:645‑658.
[4] Nunes MCP et al. “Percutaneous balloon mitral valvotomy: long‑term results in 1,200 patients.” J Am Coll Cardiol. 2021;78:1234‑1242.
[5] Centers for Disease Control and Prevention. “Strep Throat.” CDC, 2024.

```